Oncology
Revealing the molecular mechanism of tumor development and identifying the matching inhibitory candidates is one important area within the cancer research.
The tumor diversity is extremely high. Therefore, cancer research belongs to the high variant research areas with manifold scientific approaches.
To match this challenge, we offer you a unique diversity of products for your oncology research and development in the academic and pharmaceutical field.
Click on the organs and learn more about cancer types
General information
Oncologists focus on the diagnosis, therapy and follow-up of cancer.
Cancer is a class of diseases in which cells start to divide uncontrollably and invade other tissues. Cancer cells can spread to other parts of the body via the blood and lymphatic system. Under physiological conditions, cell proliferation is tightly controlled by many mechanisms. In addition, the immune system is able to recognize and destroy cancer cells. If these mechanisms fail or the immune system cannot effectively destroy the cells, it can lead to a malignant tumor. Theoretically, a malignant neoplasm can occur everywhere, but there are cancers that are more often than others. For men it is the prostate and in women it is the mammary gland.
Relevant products for oncology research
| Name | Price | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MAP3K13 (LZK) Antibody (C-term) | Login | MAP3K13 (LZK) Antibody (C-term) | ||||||||||||||||
|
||||||||||||||||||
| CD24 Antibody (N-Term) | Login | CD24 Antibody (N-Term) | ||||||||||||||||
|
||||||||||||||||||
| CD24 Antibody (N-Term) | Login | CD24 Antibody (N-Term) | ||||||||||||||||
|
||||||||||||||||||
| Anti-VEGFR2 / KDR / CD309 Reference Antibody (alacizumAb) | Login | Anti-VEGFR2 / KDR / CD309 Reference Antibody (alacizumAb) | ||||||||||||||||
|
||||||||||||||||||
| Anti-CD47 Reference Antibody (ligufalimab) | Login | Anti-CD47 Reference Antibody (ligufalimab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-CTLA-4 / CD152 Reference Antibody (quavonlimab) | Login | Anti-CTLA-4 / CD152 Reference Antibody (quavonlimab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-PDCD1 / PD-1 / CD279 Reference Antibody (penpulimab) | Login | Anti-PDCD1 / PD-1 / CD279 Reference Antibody (penpulimab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-CALCA / CGRP Reference Antibody (fremanezumab) | Login | Anti-CALCA / CGRP Reference Antibody (fremanezumab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-PDCD1 / PD-1 / CD279 Reference Antibody (balstilimab) | Login | Anti-PDCD1 / PD-1 / CD279 Reference Antibody (balstilimab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-B7-H3 / CD276 Reference Antibody (Vobramitamab) | Login | Anti-B7-H3 / CD276 Reference Antibody (Vobramitamab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-TNFRSF5 / CD40 Reference Antibody (mitazalimab) | Login | Anti-TNFRSF5 / CD40 Reference Antibody (mitazalimab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-ERBB1 / EGFR / HER1 Reference Antibody (Serclutamab talirine) | Login | Anti-ERBB1 / EGFR / HER1 Reference Antibody (Serclutamab talirine) | ||||||||||||||||
|
||||||||||||||||||
| Anti-B7-H3 / CD276 Reference Antibody (omburtamab) | Login | Anti-B7-H3 / CD276 Reference Antibody (omburtamab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-CA9 / CAIX Reference Antibody (girentuximab) | Login | Anti-CA9 / CAIX Reference Antibody (girentuximab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-Siglec-3 / CD33 Reference Antibody (vadastuximab talirine) | Login | Anti-Siglec-3 / CD33 Reference Antibody (vadastuximab talirine) | ||||||||||||||||
|
||||||||||||||||||
| Anti-VEGFB Reference Antibody (CSL346) | Login | Anti-VEGFB Reference Antibody (CSL346) | ||||||||||||||||
|
||||||||||||||||||
| Anti-B7-H3 / CD276 Reference Antibody (mirzotamAb) | Login | Anti-B7-H3 / CD276 Reference Antibody (mirzotamAb) | ||||||||||||||||
|
||||||||||||||||||
| Anti-CD19 Reference Antibody (coltuximab) | Login | Anti-CD19 Reference Antibody (coltuximab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-HGFR / c-Met Reference Antibody (SAIT301) | Login | Anti-HGFR / c-Met Reference Antibody (SAIT301) | ||||||||||||||||
|
||||||||||||||||||
| Anti-MER / MERTK Reference Antibody (RGX-019) | Login | Anti-MER / MERTK Reference Antibody (RGX-019) | ||||||||||||||||
|
||||||||||||||||||
| Anti-MUC16 Reference Antibody (sofituzumab) | Login | Anti-MUC16 Reference Antibody (sofituzumab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-NCAM1 / CD56 Reference Antibody (lorvotuzumab) | Login | Anti-NCAM1 / CD56 Reference Antibody (lorvotuzumab) | ||||||||||||||||
|
||||||||||||||||||
| Anti-ANGPT2 Reference Antibody (Roche patent anti-ANG-2) | Login | Anti-ANGPT2 Reference Antibody (Roche patent anti-ANG-2) | ||||||||||||||||
|
||||||||||||||||||
| Anti-ANO1 / TMEM16A Reference Antibody (Novartis patent anti-TMEM16A ) | Login | Anti-ANO1 / TMEM16A Reference Antibody (Novartis patent anti-TMEM16A ) | ||||||||||||||||
|
||||||||||||||||||
| Anti-AXL / UFO Reference Antibody (ORY012) | Login | Anti-AXL / UFO Reference Antibody (ORY012) | ||||||||||||||||
|
||||||||||||||||||


